HexemBio is developing regenerative therapies based on the Synthetic Human Yolk Sac, a technology designed to rejuvenate aging blood stem cells by recreating the developmental environment where they first arise. By restoring the regenerative capacity of a patient's own hematopoietic stem cells, HexemBio aims to improve outcomes in bone marrow transplantation and unlock new approaches to extending human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from New York City and from Berkeley.

To learn more, visit hexemb.io.

HexemBio

Org chart

Teams

Offices